Bio-Rad Laboratories ( (BIO)) just unveiled an update. Bio-Rad Laboratories reported first-quarter 2026 results on April 30, 2026, showing total net sales of $592.1 million, up 1.1% year-on-year, but ...

Bio-Rad Laboratories (NYSE:BIO) reported second-quarter revenue of approximately $651 million, essentially flat from $652 ...

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally ...

Have you assessed how the international operations of Bio-Rad Laboratories (BIO) performed in the quarter ended June 2026? For this maker of instruments used in biomedical research, possessing an ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Bio-Rad (BIO) delivered earnings and revenue surprises of +11.97% and -0.97%, respectively, for the quarter ended June 2026.

Q2 earnings and new guidance put Bio-Rad Laboratories in focus Bio-Rad Laboratories (BIO) drew investor attention after ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Fintel reports that on October 1, 2024, Citigroup upgraded their outlook for Bio-Rad Laboratories (NYSE:BIO) from Neutral to Buy. As of September 25, 2024, the average one-year price target for ...

Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...

Bio-Rad Laboratories plans to cut jobs and close certain facilities as part of a push aimed at bolstering its performance.